Compare FELE & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FELE | COGT |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 1995 | 2018 |
| Metric | FELE | COGT |
|---|---|---|
| Price | $96.71 | $30.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $118.50 | $55.82 |
| AVG Volume (30 Days) | 229.9K | ★ 2.0M |
| Earning Date | 10-27-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $2,131,250,000.00 | $7,871,000.00 |
| Revenue This Year | $6.41 | N/A |
| Revenue Next Year | $5.72 | $4,789.59 |
| P/E Ratio | $125.81 | ★ N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $89.54 | $13.79 |
| 52 Week High | $115.82 | $43.73 |
| Indicator | FELE | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 31.60 |
| Support Level | $95.08 | N/A |
| Resistance Level | $102.40 | $37.69 |
| Average True Range (ATR) | 1.76 | 1.31 |
| MACD | 0.42 | -0.03 |
| Stochastic Oscillator | 39.85 | 29.39 |
Franklin Electric Co Inc designs, manufactures, and distributes water and fuel pumping systems, composed of submersible motors, pumps, electronic controls, water treatment systems, and related parts and equipment. It has three segments; The Water Systems segment designs, manufactures and sells motors, pumps, drives, electronic controls, monitoring devices, and related parts and equipment for use in groundwater, water transfer, and wastewater, The Energy Systems segment designs, manufactures and sells pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment for use in fueling system applications and the Distribution segment sells and provides presale support and specifications to the installing contractors.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.